XBL * A subsidiary of Lab Testing Division, WuXi AppTec Inc. WuXi AppTec XBL * A subsidiary of Lab Testing Division, WuXi AppTec Inc. WuXi AppTec
Friday, April 20, 2018

XenoBiotic Laboratories Expands Bioanalytical Resources

Plainsboro, NJ, June 1, 2005 - XenoBiotic Laboratories, Inc. (XBL) has expanded its bioanalytical resources highlighted by the recent acquisition of a state-of-the-art API 5000 from Applied Biosystems/MDS Sciex. The API 5000 is the latest addition to the API family of triple quadrupole mass spectrometers. The system sets a new industry standard with an average nine-fold increase in sensitivity and four-fold improvement in signal-to-noise ratio over other commercial systems. The increased sensitivity of the API 5000 enhances XBL's current lineup of LC/MS/MS systems - which also includes the AB/MDS Sciex 4000 Q-Trap, 4000 Q-Star XL, and API 4000- providing the most sensitive and accurate mass quantification for drug metabolism and pharmacokinetic (DMPK) studies, as well as for absorption, distribution, metabolism, excretion, toxicity (ADMET) studies. XBL has also acquired an additional API 4000 spectrometer and a Tomtec Quadra 3 SPE liquid handling workstation.

Of course, XBL's commitment to resource expansion extends beyond excellence in LC/MS/MS systems; XBL has also welcomed several key scientists and support personnel to its bioanalytical team.

XBL strives to offer the latest advances in technology, advances that bring greater value to the core services it provides to the pharmaceutical, biotechnology, animal health and agrochemical industries. This latest expansion of resources in the bioanalytical group demonstrates XBL's continuing commitment to the highest quality bioanalytical and metabolism services.